NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
A.R. Mato, New York, NY (USA), et al.
Authors Conclusion from the abstract: The triple combination of umbralisib + ublituximab + pembrolizumab was well‐tolerated. Responses were durable in BTK refractory, high risk pts, including two CRs in RT pts. Data suggests that time‐limited therapy could be possible. Enrollment is ongoing in both the CLL and RT cohorts and an amendment is planned to evaluate the triplet combination of U2 + TG‐1501 (PD‐L1 mAb).
S.D. Smith, Seattle, WA (USA), et al.
Authors Conclusion from the abstract: P + RCHOP did not show toxicity beyond what is expected with RCHOP, and was associated with a high CR rate in this trial. FDG avid lesions in pts with PR were commonly false positives. Significant PDL‐1 tumor staining was seen in most pts tested, and appears to predict PFS; final PDL‐1 results will be presented. Our data supports further comparative study of P+RCHOP in DLBCL.
C.S. Tam, Melbourne (Australia), et al.
Authors Conclusion from the abstract: The combination of zanubrutinib plus obinutuzumab was generally well tolerated and active in patients with CLL/SLL and R/R FL. Few patients discontinued due to AEs. A Phase 2 trial comparing zanubrutinib plus obinutuzumab against obinutuzumab alone in R/R FL is ongoing.
T. Shree, Stanford, CA (USA), et al.
Authors Conclusion from the abstract: Early data suggest that the combination of oral ibrutinib, intratumoral CpG, and local low‐dose radiation is safe and can generate systemic antitumor immune responses and systemic tumor shrinkage in low‐grade lymphoma.
C. Diefenbach, New York, NY (USA), et al.
Authors Conclusion from the abstract: All combinations were well tolerated, with mainly grade 1‐2 immune toxicities, however deaths secondary to pneumonitis were noted in N containing cohorts. The ORR and CR rate in the N containing cohorts is superior to that of B‐I doublet; the CR of B‐N‐I is higher than both doublet combinations and some patients have durable responses. It remains to be seen if a higher CR rate will eventually translate into more durable response rates. The ongoing randomized phase 2 study (E4412) is comparing the B‐N doublet to the B‐N‐I triplet (NCT01896999).
T.E. Cummin, Southampton (UK), et al.
Authors Conclusion from the abstract: We identified a varied landscape of expression of anti‐apoptotic BCL‐2 proteins in DLBCL and highlighted the contribution of high BCL‐xL expression to treatment resistance in DLBCL. High expression of anti‐apoptotic BCL‐2 family members also provides resistance to BETi. However, this could be overcome by use of specific BH3‐mimetics targeting the relevant pro‐survival BCL‐2 member, involving mitochondrial priming.